BeiGene Raises New Funds For Oncology Pipeline
This article was originally published in PharmAsia News
Executive Summary
Chinese bioventure BeiGene has raised additional funding from existing and new investors, providing it with new resources to take forward through early clinical trials several molecules for cancer.
You may also be interested in...
Merck Invests In China Oncology Start-up BeiGene
Merck & Co. affiliate MSD has invested an undisclosed amount of debt and equity financing in the Beijing-based start-up biotech BeiGene, Ltd., BeiGene announced May 2
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.